Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced that Ronald Filippo has been appointed Chief Information Officer.
Mr. Filippo has more than 25 years of digital experience in the biopharmaceutical industry and was previously Senior Vice President Digital at Moderna, where he was responsible for technology leadership and digital transformation across core operations during the commercialization of the company’s COVID-19 vaccine.
Bill Sibold, Chief Executive Officer of Madrigal, stated, “Ron’s skillset and depth of digital experience will be a tremendous asset for Madrigal as we prepare for a first-to-market launch of resmetirom. His appointment reflects our commitment to leveraging AI and other digital technologies to enhance our business across the value chain, fulfill our ambitions for long-term growth, and innovate on behalf of patients with NASH.”
While at Moderna, Mr. Filippo led the digital function across the company’s core operations, most recently for a breakthrough personalized cancer vaccine, leveraging programs in AI, robotics, and equipment automation to optimize the manufacturing cycle and patient experience at launch. From 2008 to 2021, Mr. Filippo held positions of increasing responsibility at Teva Pharmaceuticals from R&D through Commercial, most recently as Head of Data and AI Transformation for North America, where he developed a comprehensive data and AI strategy for the company’s commercial operations. Mr. Filippo began his career in the biopharmaceutical industry at Schering-Plough, supporting information technology operations in R&D and Quality. He holds a B.S. degree in Information Systems from Thomas Jefferson University.
Mr. Filippo stated, “I look forward to working with the Madrigal team to enhance the company’s information technology and AI capabilities during a pivotal period of growth and transformation. We have an exciting opportunity to build on Madrigal’s legacy of scientific innovation with new digital strategies that will improve care for patients with NASH.”’
SOURCE: GlobeNewswire
